Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza Patients

Journal of Pharmaceutical Sciences

Volumn 108, Issue 9, 2019, Pages 3112-3117

  Koshimichi, Hiroki ^a   Ishibashi, Toru ^a   Wajima, Toshihiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

baloxavir marboxil; cap dependent endonuclease inhibitor; influenza; Japanese; pediatrics; population pharmacokinetics; S 033188

Indexed keywords

BALOXAVIR MARBOXIL; ANTIVIRUS AGENT; BALOXAVIR; OXAZINE DERIVATIVE; PRODRUG; PYRIDINE DERIVATIVE; THIEPIN DERIVATIVE; TRIAZINE DERIVATIVE;

ABSORPTION LAG TIME; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN CELL; INFANT; INFLUENZA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; PHARMACOKINETIC PARAMETERS; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; SCHOOL CHILD; ADULT; AGE; BAYES THEOREM; BIOLOGICAL MODEL; BIOLOGICAL VARIATION; BLOOD; DOSE RESPONSE; HALF LIFE TIME; JAPAN; METABOLIC CLEARANCE RATE; PHYSIOLOGY; PRESCHOOL CHILD;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; BAYES THEOREM; BIOLOGICAL VARIATION, POPULATION; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; INFANT; INFLUENZA, HUMAN; JAPAN; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; OXAZINES; PRODRUGS; PYRIDINES; THIEPINS; TRIAZINES;

EID: 85065549882     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2019.04.010     Document Type: Article

References (12)

1. U.S. Food and Drug Administration. Xofluza: package insert. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf, 2018. (Accessed 7 May 2019)
2. Shionogi & Co., Ltd. Xofluza: Package Insert. 2018, Shionogi & Co., Ltd, Osaka, Japan Available at http://www.info.pmda.go.jp/go/pack/6250047F1022_1_06/ (In Japanese). (Accessed 7 May 2019)
3. Koshimichi, H., Ishibashi, T., Kawaguchi, N., Sato, C., Kawasaki, A., Wajima, T., Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin Drug Investig 38 (2018), 1189–1196.
4. Fukao, K., Noshi, T., Yamamoto, A., et al. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. J Antimicrob Chemother 74:3 (2019), 654–662.
5. Koshimichi, H., Tsuda, Y., Ishibashi, T., Wajima, T., Population pharmacokinetic and exposure-response analyses of baloxavir marboxil in adults and adolescents including influenza patients. J Pharm Sci 108 (2019), 1896–1904.
6. Schwartz, G.J., Brion, L.P., Spitzer, A., The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34 (1987), 571–590.
7. Ette, E.I., Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37 (1997), 486–495.
8. Bergstrand, M., Hooker, A.C., Wallin, J.E., Karlsson, M.O., Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13 (2011), 143–151.
9. Holford, N.H., A size standard for pharmacokinetics. Clin Pharmacokinet 30 (1996), 329–332.
10. Hyden, F., Sugaya, N., Hirotsu, N., et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 379 (2018), 913–923.
11. Hirotsu N, Sakaguchi H, Sato C, et al. Baloxavir marboxil in Japanese pediatric patients with influenza: safety, pharmacokinetics and clinical and virologic outcomes. (under submission).
12. Anderson, B.J., Holford, N.H., Tips and traps analyzing pediatric PK data. Paediatr Anaesth 21 (2011), 222–237.